Orocidin, Syngene develop cGMP manufacturing process for peptide therapy

3 hours ago 1

Orocidin A/S, a unit of Nordicus Partners (OTCQB:NORD), said on Monday it has developed a cGMP-compliant manufacturing process for its antimicrobial peptide QR-01 in collaboration with Syngene International.
The process achieved over 99% purity and will support production for Orocidin’s planned Phase IIA study in patients with advanced gum disease.
Orocidin said Syngene’s team helped overcome synthesis and purification challenges by optimizing solid-phase peptide synthesis and purification steps to improve yield and solubility.
NORD closed -7.40% at $5.0.
Source: Press Release